264 related articles for article (PubMed ID: 21351231)
1. Sustained long-term benefit of patent foramen ovale closure on migraine.
Trabattoni D; Fabbiocchi F; Montorsi P; Galli S; Teruzzi G; Grancini L; Gatto P; Bartorelli AL
Catheter Cardiovasc Interv; 2011 Mar; 77(4):570-4. PubMed ID: 21351231
[TBL] [Abstract][Full Text] [Related]
2. Patent foramen ovale and migraine headaches: the saga continues.
Tobis J
Catheter Cardiovasc Interv; 2011 Mar; 77(4):575-6. PubMed ID: 21351232
[No Abstract] [Full Text] [Related]
3. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
[TBL] [Abstract][Full Text] [Related]
4. Patent foramen ovale--assessment and treatment.
Irwin B; Ray S
Cardiovasc Ther; 2012 Jun; 30(3):e128-35. PubMed ID: 21883994
[TBL] [Abstract][Full Text] [Related]
5. Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients with high-risk anatomic and functional characteristics for paradoxical embolism.
Rigatelli G; Dell'Avvocata F; Ronco F; Cardaioli P; Giordan M; Braggion G; Aggio S; Chinaglia M; Rigatelli G; Chen JP
JACC Cardiovasc Interv; 2010 Mar; 3(3):282-7. PubMed ID: 20298985
[TBL] [Abstract][Full Text] [Related]
6. Implantation of a second Amplatzer device to eliminate residual shunt after transcatheter patent foramen ovale closure.
Chessa M; Citro R; Butera G; Provenza G; Bossone E; Carminati M
J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):736-7. PubMed ID: 19483639
[TBL] [Abstract][Full Text] [Related]
7. Very late patent foramen ovale occluder device embolization.
Gaspardone A; Giardina A; Gioffrè G; Iamele M; Borioni R
J Cardiovasc Med (Hagerstown); 2011 Apr; 12(4):282-4. PubMed ID: 21386687
[No Abstract] [Full Text] [Related]
8. Closure of persistent foramen ovale with the BioSTAR biodegradable PFO closure device: feasibility and long-term outcome.
Karagianni A; Abrahamsson P; Furenäs E; Eriksson P; Dellborg M
Scand Cardiovasc J; 2011 Oct; 45(5):267-72. PubMed ID: 21728789
[TBL] [Abstract][Full Text] [Related]
9. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of transcatheter patent foramen ovale closure in migraineurs with moderate to large right-to-left shunt and instrumental evidence of cerebrovascular damage.
Papa M; Gaspardone A; Fragasso G; Ajello S; Gioffrè G; Iamele M; Iani C; Margonato A
Am J Cardiol; 2009 Aug; 104(3):434-9. PubMed ID: 19616680
[TBL] [Abstract][Full Text] [Related]
11. Resolution of migraine by transcatheter patent foramen ovale closure with Premere Occlusion System in a preliminary series of patients with previous cerebral ischemia.
Rigatelli G; Cardaioli P; Braggion G; Giordan M; Fabio D; Aggio S; Roncon L; Chinaglia M
Catheter Cardiovasc Interv; 2007 Sep; 70(3):429-33. PubMed ID: 17722021
[TBL] [Abstract][Full Text] [Related]
12. Transcatheter PFO closure with GORE(®) septal occluder: early and mid-term clinical results.
Butera G; Saracino A; Danna P; Sganzerla P; Chessa M; Carminati M
Catheter Cardiovasc Interv; 2013 Nov; 82(6):944-9. PubMed ID: 23897659
[TBL] [Abstract][Full Text] [Related]
13. New onset atrial fibrillation after patent foramen ovale closure.
Staubach S; Steinberg DH; Zimmermann W; Wawra N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2009 Nov; 74(6):889-95. PubMed ID: 19626689
[TBL] [Abstract][Full Text] [Related]
14. The BioSTAR(r) device versus the CardioSEAL(r) device in patent foramen ovale closure: comparison of mid-term efficacy and safety.
Van den Branden BJ; Luermans JG; Post MC; Plokker HW; Ten Berg JM; Suttorp MJ
EuroIntervention; 2010 Sep; 6(4):498-504. PubMed ID: 20884438
[TBL] [Abstract][Full Text] [Related]
15. Rebound increase in migraines following PFO closure.
Bhindi R; Ormerod OJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):719; author reply 720. PubMed ID: 18360874
[No Abstract] [Full Text] [Related]
16. PFO and paradoxical embolism producing events other than stroke.
Dao CN; Tobis JM
Catheter Cardiovasc Interv; 2011 May; 77(6):903-9. PubMed ID: 21207422
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
[TBL] [Abstract][Full Text] [Related]
18. Safety and long-term results of patent foramen ovale transcatheter closure in patients with thrombophilia.
Rigatelli G; Dell'Avvocata F; Giordan M; Camerotto A; Panin S; Ronco F; Cardaioli P
Minerva Cardioangiol; 2009 Jun; 57(3):285-9. PubMed ID: 19513009
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of cryptogenic stroke or TIA in patients with patent foramen ovale successfully treated by using different kind of percutaneous occluder devices: five-year follow-up.
de Cillis E; Acquaviva T; Basile DP; Cipriani F; Bortone AS
Minerva Cardioangiol; 2010 Aug; 58(4):425-31. PubMed ID: 20938409
[TBL] [Abstract][Full Text] [Related]
20. Migraine and patent foramen ovale: state of the science.
Fuller CJ; Jesurum JT
Crit Care Nurs Clin North Am; 2009 Dec; 21(4):471-91. PubMed ID: 19951764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
